SMARCA2 and cancer: A sgRNA-resistant SMARCA4 expression construct in which the SMARCA4 bromodomain is replaced with the bromodomain of BRD9 (SMARCA4res-BDBRD9) was designed to determine whether acute degradation of SMARCA4 represents a therapeutic approach against SMARCA2-deficient cancers (Fig. 5A).